Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs director Ashiya Mona received a grant of stock options covering 81,000 shares of common stock. These options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting, contingent on continued service.
Under an agreement with OrbiMed entities, any securities or economic benefits from these options must be transferred so they ultimately accrue to OrbiMed Private Investments IX, LP. This is a compensation-related award, not an open-market purchase or sale.
Shattuck Labs, Inc. director Clay B. Siegall received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting, as long as he continues serving the company. This is a compensation-related award, not an open-market purchase or sale, and results in 81,000 derivative securities held after the transaction.
Shattuck Labs director Helen M. Boudreau received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and give her the right to buy the shares in the future.
According to the terms, the 81,000 options will vest in full on the earlier of the one-year anniversary of the May 29, 2026 grant date or immediately before Shattuck Labs’ next annual meeting of stockholders, subject to her continued service. Following this grant, she holds 81,000 derivative securities directly.
Shattuck Labs, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment and restatement of the 2020 Equity Incentive Plan to increase the shares available for issuance by 1,691,082 and extend the plan’s term to March 23, 2036.
As of the April 2, 2026 record date, 75,581,787 shares of common stock were entitled to vote. All three Class III director nominees were elected, KPMG LLP was ratified as independent auditor, and the advisory vote on executive compensation passed. Stockholders favored holding future say‑on‑pay votes every year, and the company plans to conduct these votes annually.
Shattuck Labs director Clay B. Siegall increased his direct stake by exercising warrants for common stock. On May 22, 2026, he acquired 128,054 shares of common stock at an exercise price of $1.0846 per share through the exercise of warrants.
These warrants were originally issued in a private placement under an August 4, 2025 securities purchase agreement, where he bought 128,054 shares of common stock with accompanying warrants at a combined price of $0.8677 per share and warrant. Following the latest transactions, Siegall directly holds 256,108 common shares, with the exercised warrants position reduced to zero.
Shattuck Labs, Inc. Chief Technical Officer Abhinav A. Shukla reported routine equity transactions involving company stock. He received a grant or award of 5,122 shares of common stock at $1.0846 per share, increasing his direct holdings to 86,380 shares.
On the same date, he exercised warrants covering 5,122 shares of common stock at an exercise price of $1.0846 per share, eliminating this warrant position. Footnotes explain these warrants and shares stemmed from a prior private placement that included common stock and accompanying warrants issued under a securities purchase agreement.
Shattuck Labs, Inc. officer Stephen Stout reported acquiring additional equity through a private placement-related transaction. He acquired 12,805 shares of common stock and exercised accompanying warrants for 12,805 shares at an exercise price of $1.0846 per share, bringing his direct holdings to 93,366 common shares. These securities stem from a prior securities purchase agreement where common stock and warrants were originally issued together at a combined price of $0.8677 per share and warrant, with the warrants exercisable during a period tied to clinical data milestones for SL-325.
Shattuck Labs Inc. ownership filing reports that T. Rowe Price Investment Management, Inc. holds 9,865,558 shares of common stock, representing 13.8% of the class as shown for the period 03/31/2026. The filer states sole voting power for 9,831,415 shares and sole dispositive power for 9,865,558 shares. The filing is an amendment and is signed by a Vice President on 05/15/2026.
Shattuck Labs, Inc. Chief Financial Officer Andrew R. Neill reported an exercise of warrants and related share acquisition. He acquired 64,027 shares of common stock, linked to a warrant exercise covering 64,027 underlying shares at an exercise price of $1.0846 per share. Following these transactions, he directly owns 292,251 shares of common stock. No sales or dispositions were reported in this filing, and no derivative warrants remain outstanding from this grant.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported an option exercise and related share sale. He exercised stock options for 2,032 shares of common stock at an exercise price of $3.57 per share and sold 2,032 shares in an open-market transaction at a weighted average price of $7.01 per share.
The transactions were carried out under a Rule 10b5-1 trading plan adopted on February 2, 2026, designed to sell shares received from option exercises only as needed to fund exercise costs and estimated tax withholding. Following these transactions, he directly holds 81,258 shares of common stock and 50,168 stock options.